Journal
FUTURE MEDICINAL CHEMISTRY
Volume 6, Issue 16, Pages 1791-1810Publisher
FUTURE SCI LTD
DOI: 10.4155/FMC.14.119
Keywords
-
Categories
Funding
- European Commission METAFLUX [Marie Curie FP7-PEOPLE-2010 ITN-264780]
- Spanish Government [SAF2011-25726]
- European Union FEDER [SAF2011-25726]
- Generalitat de Catalunya [2014SGR-1017]
- Generalitat de Catalunya (Icrea Academia award)
Ask authors/readers for more resources
Metabolic processes are altered in cancer cells, which obtain advantages from this metabolic reprogramming in terms of energy production and synthesis of biomolecules that sustain their uncontrolled proliferation. Due to the conceptual progresses in the last decade, metabolic reprogramming was recently included as one of the new hallmarks of cancer. The advent of high-throughput technologies to amass an abundance of omic data, together with the development of new computational methods that allow the integration and analysis of omic data by using genome-scale reconstructions of human metabolism, have increased and accelerated the discovery and development of anticancer drugs and tumor-specific metabolic biomarkers. Here we review and discuss the latest advances in the context of metabolic reprogramming and the future in cancer research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available